SRPT: Sarepta Therapeutics Inc. (DE) Stocks News on July 26, 2024

SRPT

Argus Research

3 days ago

SRPT: Rating decreased to a SELL

This market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likes

SRPT

Moneywise

6 days ago

This market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likes

SRPT

Zacks

7 days ago

Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

SRPT

GlobeNewswire

9 days ago

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

SRPT

Argus Research

10 days ago

SRPT: Raising target price to $156.00

SRPT

Zacks

10 days ago

What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?

SRPT

Argus Research

17 days ago

SRPT: Rating increased to a HOLD

SRPT

Zacks

18 days ago

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD

After a Big Win, Is Sarepta Therapeutics Stock a Buy?

SRPT

Motley Fool

20 days ago

After a Big Win, Is Sarepta Therapeutics Stock a Buy?

Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?

SRPT

Motley Fool

23 days ago

Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?

1 Soaring Growth Stock to Buy and Hold for 10 Years

SRPT

Motley Fool

23 days ago

1 Soaring Growth Stock to Buy and Hold for 10 Years

Best Momentum Stocks to Buy for July 3rd

SRPT

Zacks

23 days ago

Best Momentum Stocks to Buy for July 3rd

SRPT

Argus Research

24 days ago

SRPT: Rating decreased to a SELL

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRPT

Business Wire

a month ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates

SRPT

Zacks

a month ago

Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates

Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.

SRPT

Motley Fool

a month ago

Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.

SRPT

MT Newswires

a month ago

Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172

SRPT

MT Newswires

a month ago

Citigroup Upgrades Sarepta Therapeutics to Neutral From Buy, Adjusts PT to $176 From $172

SRPT

GuruFocus.com

a month ago

Insider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval

SRPT

Investor's Business Daily

a month ago

Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval

SRPT

MT Newswires

a month ago

Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $200 From $165, Keeps Overweight Rating

SRPT

MT Newswires

a month ago

Evercore ISI Raises Price Target on Sarepta Therapeutics to $185 From $139, Maintains In Line Rating

SRPT

MT Newswires

a month ago

BMO Capital Raises Price Target on Sarepta Therapeutics to $200 From $170, Maintains Outperform Rating

SRPT

Zacks

a month ago

Company News for Jun 24, 2024

SRPT

Zacks

a month ago

Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?

What next for gas prices, how the S&P 500 can reach 6,000: Market Domination

SRPT

Yahoo Finance Video

a month ago

What next for gas prices, how the S&P 500 can reach 6,000: Market Domination

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

SRPT

Investor's Business Daily

a month ago

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

These Stocks Moved the Most Today: Nvidia, Microsoft, Trump Media, Sarepta, Palantir, Hertz, Smith & Wesson, and More

SRPT

Barrons.com

a month ago

These Stocks Moved the Most Today: Nvidia, Microsoft, Trump Media, Sarepta, Palantir, Hertz, Smith & Wesson, and More

SRPT

MT Newswires

a month ago

Sector Update: Health Care Stocks Gain in Late Afternoon

These Stocks Are Moving the Most Today: Nvidia, Microsoft, Trump Media, Sarepta, Palantir, Hertz, Smith & Wesson, and More

SRPT

Barrons.com

a month ago

These Stocks Are Moving the Most Today: Nvidia, Microsoft, Trump Media, Sarepta, Palantir, Hertz, Smith & Wesson, and More

Sarepta's Stock Soars on Best-Case FDA Decision for its Muscular Dystrophy Treatment

SRPT

The Wall Street Journal

a month ago

Sarepta's Stock Soars on Best-Case FDA Decision for its Muscular Dystrophy Treatment

SRPT

MT Newswires

a month ago

Sector Update: Health Care Stocks Edge Up in Afternoon Trading

Top Stock Movers Now: FactSet, Sarepta Therapeutics, Spirit AeroSystems, and More

SRPT

Investopedia

a month ago

Top Stock Movers Now: FactSet, Sarepta Therapeutics, Spirit AeroSystems, and More

US indexes open mixed, pharmaceutical stocks climb: Morning Brief

SRPT

Yahoo Finance Video

a month ago

US indexes open mixed, pharmaceutical stocks climb: Morning Brief

Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone

SRPT

Investor's Business Daily

a month ago

Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone

Stocks to Watch Friday: Nvidia, Micron, Sarepta, CarMax

SRPT

The Wall Street Journal

a month ago

Stocks to Watch Friday: Nvidia, Micron, Sarepta, CarMax

SRPT

MT Newswires

a month ago

Sarepta Therapeutics' Gets Label Expansion for Elevidys in 'Best-case Scenario,' BofA Securities Says

Sarepta surges on expanded approval of muscular dystrophy drug

SRPT

Yahoo Finance Video

a month ago

Sarepta surges on expanded approval of muscular dystrophy drug

SRPT

MT Newswires

a month ago

Sector Update: Health Care

Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug

SRPT

Investopedia

a month ago

Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug

SRPT

MT Newswires

a month ago

BofA Securities Adjusts Sarepta Therapeutics Price Target to $213 From $166, Maintains Buy Rating

SRPT

MT Newswires

a month ago

Oppenheimer Adjusts Sarepta Therapeutics Price Target to $215 From $180, Maintains Outperform Rating

SRPT

MT Newswires

a month ago

Needham Raises Price Target on Sarepta Therapeutics to $235 From $166, Maintains Buy Rating

Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks.

SRPT

Barrons.com

a month ago

Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks.

Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy

SRPT

Investor's Business Daily

a month ago

Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy

Sarepta Jumps on Broad Approval for Muscular Dystrophy Drug

SRPT

Bloomberg

a month ago

Sarepta Jumps on Broad Approval for Muscular Dystrophy Drug

SRPT

MT Newswires

a month ago

Sarepta Therapeutics Gets Expanded US FDA Approval for Treatment of Duchenne Muscular Dystrophy; Shares Soar After Hours

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

SRPT

Business Wire

a month ago

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

SRPT

Investing.com

a month ago

Sarepta Therapeutics surges 36% after-hours following expanded FDA approval

Sarepta Duchenne gene therapy wins broader use from FDA

SRPT

BioPharma Dive

a month ago

Sarepta Duchenne gene therapy wins broader use from FDA

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test

SRPT

Investor's Business Daily

a month ago

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test

Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival

SRPT

Barrons.com

a month ago

Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival

Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision

SRPT

BioPharma Dive

a month ago

Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision

SRPT

Business Wire

2 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRPT

Zacks

2 months ago

Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?

SRPT

MT Newswires

2 months ago

Sector Update: Health Care

SRPT

MT Newswires

2 months ago

Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400

Sarepta Therapeutics Set to Join S&P MidCap 400

SRPT

PR Newswire

2 months ago

Sarepta Therapeutics Set to Join S&P MidCap 400

SRPT

Insider Monkey

2 months ago

Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A Good Fast Growth Stock To Buy?

SRPT

MT Newswires

2 months ago

Sarepta Therapeutics Shares Fall After RBC Downgrade

SRPT

MT Newswires

2 months ago

RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Lowers Price Target to $142 From $157

SRPT

Zacks

2 months ago

Implied Volatility Surging for Sarepta (SRPT) Stock Options

SRPT

MT Newswires

2 months ago

Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating

SRPT

MT Newswires

2 months ago

Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180

Earnings Beat: Sarepta Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

SRPT

Simply Wall St.

3 months ago

Earnings Beat: Sarepta Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

SRPT

Business Wire

3 months ago

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

SRPT

MT Newswires

3 months ago

Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says

SRPT

MT Newswires

3 months ago

UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating

SRPT

Zacks

3 months ago

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

SRPT

Insider Monkey

3 months ago

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript

SRPT

MT Newswires

3 months ago

Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating

SRPT

Thomson Reuters StreetEvents

3 months ago

Q1 2024 Sarepta Therapeutics Inc Earnings Call

SRPT

GuruFocus.com

3 months ago

Sarepta Therapeutics Inc (SRPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...

SRPT

Zacks

3 months ago

Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

SRPT

Motley Fool

3 months ago

Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript

SRPT

Zacks

3 months ago

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates

SRPT

MT Newswires

3 months ago

Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours

SRPT

Associated Press Finance

3 months ago

Sarepta Therapeutics: Q1 Earnings Snapshot

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

SRPT

Business Wire

3 months ago

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

1 Top Growth Stock to Buy and Hold for 10 Years

SRPT

Motley Fool

3 months ago

1 Top Growth Stock to Buy and Hold for 10 Years

SRPT

Business Wire

3 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRPT

Zacks

3 months ago

Why Sarepta (SRPT) Might Surprise This Earnings Season

Sarepta Therapeutics Stock Shows Improved Technical Strength

SRPT

Investor's Business Daily

3 months ago

Sarepta Therapeutics Stock Shows Improved Technical Strength

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

SRPT

Zacks

3 months ago

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for

SRPT

Zacks

3 months ago

Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for

Bullish Sarepta Therapeutics Insiders Loaded Up On US$13.3m Of Stock

SRPT

Simply Wall St.

3 months ago

Bullish Sarepta Therapeutics Insiders Loaded Up On US$13.3m Of Stock

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

SRPT

Business Wire

3 months ago

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

10 Unstoppable Stocks That Will Make You Richer

SRPT

Insider Monkey

3 months ago

10 Unstoppable Stocks That Will Make You Richer

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst

SRPT

Investor's Business Daily

4 months ago

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst

2 Biotech Stocks to Buy Hand Over Fist in April

SRPT

Motley Fool

4 months ago

2 Biotech Stocks to Buy Hand Over Fist in April

Outperforming ETF manager names a potential ‘50-bagger’ in the stock market

SRPT

MarketWatch

4 months ago

Outperforming ETF manager names a potential ‘50-bagger’ in the stock market

SRPT

Business Wire

4 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRPT

Zacks

4 months ago

Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

SRPT

Simply Wall St.

4 months ago

Sarepta Therapeutics' (NASDAQ:SRPT) growing losses don't faze investors as the stock increases 3.6% this past week

A Comprehensive Look at Sarepta's Growth and Innovation

SRPT

GuruFocus.com

4 months ago

A Comprehensive Look at Sarepta's Growth and Innovation

30 Biggest Biotechnology Companies in the World

SRPT

Insider Monkey

4 months ago

30 Biggest Biotechnology Companies in the World

Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks

SRPT

Insider Monkey

4 months ago

Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

SRPT

Motley Fool

4 months ago

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

SRPT

GuruFocus.com

5 months ago

Director Wigzell Hans Lennart Rudolf Sells 15,000 Shares of Sarepta Therapeutics Inc (SRPT)

Billionaire Ray Dalio and Insiders Love These 10 Stocks

SRPT

Insider Monkey

5 months ago

Latest Sarepta Therapeutics Inc. (DE) (SRPT) News on July 26, 2024

Share on Social Networks: